Boston Scientific (BSX) return on equity (ROE)

Return on equity · fiscal 2025
12.0%

Boston Scientific (BSX) earned a return on equity of 12.0% in fiscal 2025 (the year ended December 31, 2025). That is 3.4 percentage points higher than the 8.5% of fiscal 2024. Figures as of 17 Nov 2026, 22:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
12.0%
Change on fiscal 2024
+3.4 pts
Highest on record
33.9%fiscal 2019
Lowest on record
-59.2%fiscal 2012
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Boston Scientific return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 33.9% in fiscal 2019 and the lowest -59.2% in fiscal 2012. The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 1.5%.

History · 18 fiscal years

Return on equity by fiscal year

Boston Scientific return on equity (ROE), year by year

Boston Scientific (BSX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202512.0% 3.4 pts up
20248.5% 0.3 pts up
20238.3% 4.3 pts up
20224.0% 2.3 pts down
20216.3% 6.8 pts up
2020-0.5% 34.4 pts down
201933.9% 14.7 pts up
201819.1% 17.7 pts up
20171.5% 3.7 pts down
20165.2% 8.9 pts up
2015-3.8% 1.9 pts down
2014-1.8% 0.0 pts
2013-1.9% 57.4 pts up
2012-59.2% 63.1 pts down
20113.9% 13.3 pts up
2010-9.4% 1.1 pts down
2009-8.3% 7.1 pts up
2008-15.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Boston Scientific and comparable companies
CompanyReturn on equityFiscal year
Takeda Pharmaceutical TAK-2.1%2026
Cencora COR103.1%2025
Boston Scientific BSX12.0%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BSX

Boston Scientific, figure by figure

Boston Scientific (BSX) overview: price, valuation and scorecardAll health care companies by market value

Boston Scientific return on equity (ROE): questions and answers

What is Boston Scientific's return on equity?

Boston Scientific (BSX) earned a return on equity of 12.0% in fiscal 2025 (the year ended December 31, 2025). That is 3.4 percentage points higher than the 8.5% of fiscal 2024.

Is Boston Scientific's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 88% of the 17 earlier fiscal years on record, whose median is 1.5%.

What are the highest and lowest return on equity figures on record for Boston Scientific?

Across the 18 fiscal years on record (2008–2025), the highest was 33.9% in fiscal 2019 and the lowest -59.2% in fiscal 2012.

How is Boston Scientific's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Boston Scientific (BSX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BSX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.